产品: 磷酸化 IGF1R/Insulin Receptor (Tyr1161) 抗体
货号: AF3125
描述: Rabbit polyclonal antibody to Phospho-IGF1R/Insulin Receptor (Tyr1161)
应用: WB IHC IF/ICC IP
文献验证: WB, IF/ICC
反应: Human, Mouse, Rat
预测: Bovine, Rabbit, Dog, Chicken, Xenopus
蛋白号: P08069 | P06213
RRID: AB_2834560

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1300 现货
 100ul RMB¥ 2400 现货
 200ul RMB¥ 3200 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IP, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-IGF1R/Insulin Receptor (Tyr1161) Antibody detects endogenous levels of IGF1R/Insulin Receptor only when phosphorylated at Tyrosine 1161.
RRID:
AB_2834560
引用格式: Affinity Biosciences Cat# AF3125, RRID:AB_2834560.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

CD221; CD221 antigen; IGF 1 receptor; IGF 1R; IGF I receptor; IGF-I receptor; Igf1r; IGF1R_HUMAN; IGFIR; IGFIRC; IGFR; Insulin like growth factor 1 receptor; Insulin like growth factor 1 receptor precursor; Insulin-like growth factor 1 receptor beta chain; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172; MGC18216; Soluble IGF1R variant 1; Soluble IGF1R variant 2; CD220; HHF5; HIR B; INSR; Insulin receptor; Insulin receptor subunit beta; IR;

抗原和靶标

免疫原:

A synthesized peptide derived from human IGF1R/Insulin Receptor around the phosphorylation site of Tyr1161.

基因/基因ID:
描述:
InsR a receptor tyrosine kinase that binds insulin and key mediator of the metabolic effects of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K).

研究领域

· Cellular Processes > Cell growth and death > Oocyte meiosis.   (View pathway)

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway - multiple species.   (View pathway)

· Organismal Systems > Nervous system > Long-term depression.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Ovarian steroidogenesis.

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.

· Organismal Systems > Excretory system > Aldosterone-regulated sodium reabsorption.

文献引用

1). Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease-On Network Pharmacology and Experimental Evaluation. Frontiers in pharmacology, 2022 (PubMed: 35140607) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 8. Diosgenin induces apoptosis in Nthy-ori 3-1 cells by inhibiting the phosphorylation of IGF-1R in vitro phosphorylation of IGF-1R in vitro. (A) Cell viability with IGF-1 (ng/ml) at increasing concentrations after culturing for 48 h. (B) Cell viability after 24 h of culture with diosgenin (μM) at different concentrations. (C) Cell viability with IGF1 (100 ng/ml) and diosgenin (μM) at different concentrations. (D) Apoptosis-related proteins were detected using WB as described above. ß-actin was used as an internal reference. (F) Diosgenin devitalized the PI3K/AKT and Raf1/MEK signaling pathways by inhibiting p-IGF-1R. (E, G–I) Data are shown as the mean ± standard deviation of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 compared with the 0 group. #p < 0.05 compared with the IGF-1 group.

2). Activation of Hippocampal IR/IRS-1 Signaling Contributes to the Treatment with Zuogui Jiangtang Jieyu Decoction on the Diabetes-Related Depression. Evidence-based Complementary and Alternative Medicine, 2021 (PubMed: 34149862)

Application: WB    Species: Rat    Sample: hippocampus tissue

Figure 3 ZJJ activated the hippocampal insulin signaling pathway in diabetic rats. (a) Bands of p-IR, IR, p-IRS-1, IRS-1, p-PI3K, PI3K, p-AKT, AKT, and GAPDH. (b–e) Both doses of ZJJ treatment increased the expression of p-IR (b), while the high dose of ZJJ treatment increased the expression of p-IRS-1 (c), p-PI3K (d), and p-AKT (e) in diabetic rats. n = 6 in each group. ##P < 0.01 and ##P < 0.05 vs. the control group. ∗∗P < 0.01 and ∗P < 0.05 vs. the DM group. Data are presented as the mean ± SEM.

Application: IF/ICC    Species: Rat    Sample: hippocampus tissue

Figure 4 ZJJ activated the neuronal insulin signaling pathway in diabetic rats. (a) Immunofluorescence analysis of p-IR, p-IRS-1, p-PI3K, and p-AKT. (b–e) Both doses of ZJJ treatment increased the immunopositivity of p-IR (b), while the high dose of ZJJ treatment increased the expression of p-IRS-1 (c), p-PI3K (d), and p-AKT (e) in the hippocampus of diabetic rats. n = 5 in each group. Bar = 50 μm. ##P < 0.01 vs. the control group. ∗∗P < 0.01 and ∗P < 0.05 vs. the DM group. Data are presented as the mean ± SEM.

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.